QuidelOrtho Corp. Stock Plummets to New 52-Week Low at $15.08

QuidelOrtho Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 15.08 as of March 20, 2026. This marks a significant decline, with the stock's performance over the past year showing a decrease of 62.94%, starkly contrasting with the S&P 500's gain of 14.9% during the same period. The company has faced ongoing financial difficulties, reporting negative results for the last 12 consecutive quarters. Key financial metrics reveal a debt-equity ratio of 1.31, indicating a higher reliance on debt, while the return on equity stands at -7.95%. Additionally, the price-to-book ratio is notably low at 0.63, suggesting that the stock may be undervalued relative to its assets. QuidelOrtho's performance has consistently lagged behind the S&P 500 over the past three years, with a staggering decline of 56.32% in the last year alone. As the company navigates these challenges, its market capitalization is currently at USD 1,202 million, reflecting its small-cap status in a competitive industry.